GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Meta] the FLOW rule is doing its job and people should stop complaining — 44 comments in the full submission. View in context.
1.4k
c/trialwatch·submitted 1 months ago by u/careful_gradient_again

[Meta] the FLOW rule is doing its job and people should stop complaining

Trial Databranch of 7 comments

Putting this to the board: the FLOW rule is doing its job and people should stop complaining. Why comparing across trials almost never works, with the specific failure modes. Different populations: an obesity programme and a diabetes programme enrol different people with different baseline characteristics. Different…

Read the full submission and all 44 comments →

This branch

7 comments, started 1 months ago
u/ahmed_iyer26 points·1 months ago

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

replysharereportpermalink
u/nordic_pricing38 points·1 months ago

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

replysharereportpermalink
u/ewan_tulloch10 points·1 months ago

a mean is not a promise

replysharereportpermalink
u/blunt_coldbox_notes3 points·1 months ago

intention to treat versus completers changes the number substantially

replysharereportpermalink
u/careful_gradient_againOP2 points·1 months ago

trial populations get support that nobody on this board gets

replysharereportpermalink
u/careful_gradient_againOP2 points·1 months ago

Correcting myself upthread: I gave the completer figure and labelled it intention-to-treat.

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →